Philips reiterates timing of 2026 outlook
Royal Philips (NYSE: PHG) reaffirmed on 4 December 2025 that its 2026 outlook will be published on 10 February 2026 as previously scheduled.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Royal Philips (NYSE: PHG) reaffirmed on 4 December 2025 that its 2026 outlook will be published on 10 February 2026 as previously scheduled. The company said it expects continued performance improvement with sequential comparable sales growth, expanded margins despite tariff headwinds, and strong cash flow.
Philips reiterated an expectation that comparative sales growth will accelerate sequentially in 2026 toward mid-single-digit growth, supported by solid order momentum and consistent with the last four quarters. The company has not released an early view of formal guidance and will share its full outlook on 10 February 2026.
Details
News Market Reaction – PHG
On Dec 4, the day this news came out, PHG closed 4.92% below the previous close.
Data tracked by StockTitan Argus for the Dec 4 session.
Key Figures
- Outlook year
- 2026 outlook
- Company-level financial outlook year referenced in article
- Outlook publication date
- February 10
- Planned date to issue 2026 outlook
- Consecutive quarters
- 4 quarters
- Sequential performance improvement referenced as last four quarters
- Clinical procedures
- >2,000 procedures
- LumiGuide cited clinical use volume
- Procedure time reduction
- 37% faster
- Single-center study for LumiGuide procedures
- DAP reduction
- 56% reduction
- Single-center study reporting DAP reduction with LumiGuide
- FDA clearance
- Granted
- LumiGuide regulatory status in U.S.
- CE marking
- Granted
- LumiGuide regulatory status in Europe
Historical Context
-
Reaffirmed 2026 outlook with expected sales growth and stronger margins.
-
Expanded LumiGuide commercial availability with FDA clearance and CE marking.
-
Launched web-based diagnostic viewer for broader imaging access.
-
Extended Cortechs.ai partnership to integrate quantitative neuroimaging analytics.
-
Introduced DeviceGuide to assist heart valve repair with real-time 3D guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
December 4, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule.
As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit growth in line with the current trajectory and supported by continued solid order momentum. This is in line with performance in the last four consecutive quarters.
The company has not released any early view of its forthcoming guidance. Yesterday at an industry conference, in answer to a question, the company confirmed that sequential acceleration towards mid-single-digit growth continues to be its expectation and noted this does not imply doubling growth every single year in the company’s multi-year trajectory.
Philips will share its outlook as part of its planned disclosure on February 10.
For further information, please contact:
Steve Heywood
Philips Global External Relations
Tel.: +31 638 363 589
E-mail: steve.heywood@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-Mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.